Suppr超能文献

心房颤动的不良后果;机制、风险以及从治疗选择中获得的见解。

Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options.

作者信息

Johnson David L, Day John D, Mahapatra Srijoy, Bunch T Jared

机构信息

Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Murray Utah.

St. Jude Medical Corporation.

出版信息

J Atr Fibrillation. 2012 Feb 2;4(5):477. doi: 10.4022/jafib.477. eCollection 2012 Feb-Mar.

Abstract

Atrial Fibrillation (AF) continues to increase in prevalence and its' consequences and disease associations have a great impact on multiple aspects of medical practice. As such, making preventive strategies to minimize risk of the arrhythmia and its' complications are paramount to improve quality of life, mortality, and limit medical resource utilization. To the extent that AF independently impacts adverse cardiovascular outcomes, this review article will focus on these outcomes, in particular heart failure (HF), stroke, and mortality, and discuss contemporary strategies for treatment. AF has a marked deleterious impact on the lives of patients. This impact can be accelerated when other cardiac diseases coexist. Although rhythm control strategies have been an intriguing tool to reverse or minimize the adverse outcomes associate with AF, they have largely been unsuccessful. In general, failures of currently available AADs to improve survival are due to failure of the drug to maintain sinus rhythm and presence of drug toxicities. Early data with ablation approaches are favorable and support rhythm control strategies to minimize long-term risks associated with AF. However, most of the data stem from observational analysis or small randomized trials. Large randomized prospective trials will ultimately define the role of catheter ablation in the management of AF patients.

摘要

心房颤动(AF)的患病率持续上升,其后果及与疾病的关联对医疗实践的多个方面产生重大影响。因此,制定预防策略以降低心律失常及其并发症的风险对于提高生活质量、降低死亡率以及限制医疗资源利用至关重要。鉴于AF独立影响不良心血管结局,本文将聚焦于这些结局,特别是心力衰竭(HF)、中风和死亡率,并讨论当代治疗策略。AF对患者的生活有显著的有害影响。当其他心脏疾病并存时,这种影响会加剧。尽管节律控制策略一直是逆转或最小化与AF相关不良结局的有趣工具,但它们在很大程度上并不成功。一般来说,目前可用的抗心律失常药物(AADs)未能改善生存率是由于药物无法维持窦性心律以及存在药物毒性。消融方法的早期数据是有利的,并支持节律控制策略以最小化与AF相关的长期风险。然而,大多数数据来自观察性分析或小型随机试验。大型随机前瞻性试验最终将确定导管消融在AF患者管理中的作用。

相似文献

1
Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options.
J Atr Fibrillation. 2012 Feb 2;4(5):477. doi: 10.4022/jafib.477. eCollection 2012 Feb-Mar.
2
Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.
J Cardiovasc Pharmacol Ther. 2017 Jan;22(1):3-19. doi: 10.1177/1074248416651722. Epub 2016 Jul 8.
3
Atrial Fibrillation in Heart Failure-Diagnostic, Therapeutic, and Prognostic Relevance.
Curr Heart Fail Rep. 2019 Aug;16(4):108-115. doi: 10.1007/s11897-019-00430-5.
6
Rate versus rhythm control in atrial fibrillation.
Cardiol Clin. 2004 Feb;22(1):63-9. doi: 10.1016/s0733-8651(03)00112-7.
7
Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials.
JACC Clin Electrophysiol. 2015 Jun 1;1(3):200-209. doi: 10.1016/j.jacep.2015.02.018.
8
10
Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?
Pacing Clin Electrophysiol. 2011 Feb;34(2):247-59. doi: 10.1111/j.1540-8159.2010.02967.x. Epub 2010 Nov 17.

引用本文的文献

本文引用的文献

1
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med. 2011 Dec 15;365(24):2334; author reply 2335. doi: 10.1056/NEJMc1112233.
2
Dronedarone in high-risk permanent atrial fibrillation.
N Engl J Med. 2011 Dec 15;365(24):2268-76. doi: 10.1056/NEJMoa1109867. Epub 2011 Nov 14.
4
6
Apixaban versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
10
Natural history and long-term outcomes of ablated atrial fibrillation.
Circ Arrhythm Electrophysiol. 2011 Jun;4(3):271-8. doi: 10.1161/CIRCEP.111.962100. Epub 2011 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验